Renata PLC (DSE:RENATA)
446.80
0.00 (0.00%)
At close: Oct 19, 2026
Renata Revenue
In the fiscal year ending June 30, 2026, Renata had annual revenue of 46.20B BDT with 7.71% growth. Renata had revenue of 12.58B in the quarter ending June 30, 2026, with 11.19% growth. That makes Renata the 13,010th largest company in the world by revenue and 16th in Bangladesh.
Revenue
46.20B
Revenue Growth
+7.71%
P/S Ratio
1.11
Revenue / Employee
5.32M
Employees
8,366
Market Cap
51.25B
Revenue by Geography
- Bangladesh 43.46B 94.1%
- Export 2.29B 5.0%
- Ireland 436.99M 0.9%
- United Kingdom 16.97M 0.0%
Fiscal year ended Jun 30, 2026 See the full Renata breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 46.20B | 3.31B | 7.71% |
| Jun 30, 2025 | 42.89B | 5.18B | 13.74% |
| Jun 30, 2024 | 37.71B | 4.74B | 14.37% |
| Jun 30, 2023 | 32.97B | 1.90B | 6.12% |
| Jun 30, 2022 | 31.07B | 1.10B | 3.67% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Square Pharmaceuticals PLC. | 83.53B |
| Beximco Pharmaceuticals PLC. | 53.93B |
| The ACME Laboratories | 40.05B |
| Beacon Pharmaceuticals | 15.57B |
| The IBN SINA Pharmaceutical Industry | 13.48B |
| Navana Pharmaceuticals | 10.57B |
| Unilever Consumer Care | 3.42B |
| Techno Drugs | 3.10B |